MX2017007214A - Procedimiento para la expansion de linfocitos t gamma/delta. - Google Patents

Procedimiento para la expansion de linfocitos t gamma/delta.

Info

Publication number
MX2017007214A
MX2017007214A MX2017007214A MX2017007214A MX2017007214A MX 2017007214 A MX2017007214 A MX 2017007214A MX 2017007214 A MX2017007214 A MX 2017007214A MX 2017007214 A MX2017007214 A MX 2017007214A MX 2017007214 A MX2017007214 A MX 2017007214A
Authority
MX
Mexico
Prior art keywords
cells
gammadelta
cell expansion
expansion procedure
tgf
Prior art date
Application number
MX2017007214A
Other languages
English (en)
Inventor
Maher John
Esmond BEATSON Richard
Catarina Parente Pereira Puri Ana
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of MX2017007214A publication Critical patent/MX2017007214A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Abstract

Se proporciona un método para expandir una población de linfocitos T y? en el que se cultivan Células Mononucleares de Sangre Periférica (CMSP) aisladas y activadas en un medio que comprende el factor de crecimiento transformante ? (FCT-?) en condiciones en las que la producción de linfocitos T y? efectores que tienen actividad terapéutica frente a una enfermedad maligna está favorecida. El use de FCT-? en la producción de linfocitos efectores, en particular linfocitos T Vy9V?2 también se describe y se reivindica.
MX2017007214A 2014-12-05 2015-12-04 Procedimiento para la expansion de linfocitos t gamma/delta. MX2017007214A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1421716.0A GB201421716D0 (en) 2014-12-05 2014-12-05 Cell expansion procedure
PCT/GB2015/053713 WO2016087871A1 (en) 2014-12-05 2015-12-04 Gammadelta t cell expansion procedure

Publications (1)

Publication Number Publication Date
MX2017007214A true MX2017007214A (es) 2018-01-30

Family

ID=52425560

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007214A MX2017007214A (es) 2014-12-05 2015-12-04 Procedimiento para la expansion de linfocitos t gamma/delta.

Country Status (13)

Country Link
US (4) US10557117B2 (es)
EP (2) EP3696263A1 (es)
JP (1) JP6802159B2 (es)
KR (1) KR20170084337A (es)
CN (1) CN107208061A (es)
AU (1) AU2015356788B2 (es)
CA (1) CA2969783C (es)
DK (1) DK3227435T3 (es)
GB (1) GB201421716D0 (es)
MX (1) MX2017007214A (es)
RU (1) RU2017121191A (es)
WO (1) WO2016087871A1 (es)
ZA (1) ZA201704499B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure
KR102032354B1 (ko) * 2016-11-11 2019-10-16 가톨릭대학교 산학협력단 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108588023B (zh) * 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
AU2019302207A1 (en) 2018-07-13 2021-03-04 Kyoto University Method for producing γδ T cells
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
KR20210088632A (ko) * 2018-11-08 2021-07-14 인8바이오 인코포레이티드 암의 치료용 조성물 및 치료 방법
CN110184240B (zh) * 2019-06-13 2020-11-20 上海市肺科医院 一种高效扩增活化Vγ2Vδ2 T细胞增强其抗结核活性的方法
JPWO2021106832A1 (es) 2019-11-25 2021-06-03
KR20230105166A (ko) 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
CN114645022B (zh) * 2022-05-13 2022-09-02 首都医科大学宣武医院 靶向CD5的CAR-γ δ T细胞及其制备方法与应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528307B1 (en) 1997-04-25 2003-03-04 The Wistar Institute Of Anatomy And Biology Cytolytic T-cell clones against colorectal carcinoma
ATE238061T1 (de) * 1997-11-05 2003-05-15 Univ Southern California Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
EP1127107B1 (en) * 1998-11-04 2009-01-21 Therapure Biopharma Inc. Methods for the production of tcr gamma delta t cells
FR2836483B1 (fr) 2002-02-22 2006-09-15 Innate Pharma Procedes de production de lymphocytes gamma delta t
ATE441420T1 (de) 2002-12-02 2009-09-15 Innate Pharma Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
WO2005077411A2 (en) 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
WO2006006720A1 (ja) * 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
CA2576571C (en) * 2004-08-19 2013-07-02 University Of Bern Preparation of antigen-presenting human .gamma..delta. t cells and use in immunotherapy
MX2008001183A (es) 2005-07-25 2008-04-11 Therimunex Llc Peptidil diacilgliceridos.
EP2083830A1 (en) * 2006-11-17 2009-08-05 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
JPWO2008129874A1 (ja) * 2007-04-13 2010-07-22 株式会社メディネット 腫瘍細胞の標的化方法、及びその用途
ITRM20070437A1 (it) * 2007-08-10 2009-02-11 Istituto Naz Per Le Malattie I Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
DK2311470T3 (en) * 2008-07-01 2015-08-17 Medinet Co Ltd A method for simultaneous induction of CTLs and gamma delta T cells
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN105452287A (zh) 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
CN103436492B (zh) * 2013-08-02 2016-03-02 北京赛诺泰生物科技有限公司 通过无血清培养扩增活化淋巴细胞的方法
CN103436493B (zh) * 2013-08-29 2016-02-03 浙江大学 雷帕霉素诱导调节性γδT细胞的培养方法
GB201421716D0 (en) 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
KR20170084337A (ko) 2017-07-19
US11566222B2 (en) 2023-01-31
GB201421716D0 (en) 2015-01-21
RU2017121191A (ru) 2019-01-10
US20200123502A1 (en) 2020-04-23
RU2017121191A3 (es) 2019-07-29
WO2016087871A1 (en) 2016-06-09
AU2015356788B2 (en) 2021-09-30
CA2969783A1 (en) 2016-06-09
EP3696263A1 (en) 2020-08-19
AU2015356788A1 (en) 2017-07-13
JP6802159B2 (ja) 2020-12-16
JP2017537625A (ja) 2017-12-21
US20170342381A1 (en) 2017-11-30
US20200140816A1 (en) 2020-05-07
ZA201704499B (en) 2019-09-25
DK3227435T3 (da) 2020-05-04
CN107208061A (zh) 2017-09-26
US10557117B2 (en) 2020-02-11
CA2969783C (en) 2023-08-01
US20230323298A1 (en) 2023-10-12
EP3227435A1 (en) 2017-10-11
EP3227435B1 (en) 2020-01-29

Similar Documents

Publication Publication Date Title
MX2017007214A (es) Procedimiento para la expansion de linfocitos t gamma/delta.
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
MY180750A (en) Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
TR201904270T4 (tr) Tanımlı koşullar altında insan pluripotent kök hücrelerinin hematoendotelyal farklılaşması için yöntemler ve materyaller.
TW201612312A (en) Meristematic plant cells and method of isolating them
EP3436570A4 (en) MEDIUM, PROCEDURE, CELLS AND SECRETATED FACTORS FOR STEM CELL CULTURE AND THERAPY
WO2018097540A3 (ko) 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물
PH12018500371A1 (en) Clinical formulations
EP3947647A4 (en) METHODS OF MANUFACTURE OF CAR NK CELLS AND USE THEREOF
JP2017537625A5 (es)
MX2020005100A (es) Cultivo de placenta para aislar exosomas.
IL277036A (en) Expression of human FOXP3 in genetically engineered T cells
EP3279318A4 (en) Human serum albumin-containing culture medium for growth of neural stem cells
WO2015181831A3 (en) A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord
EP3866814A4 (en) METHOD OF GENERATING TISSUE-RESIDENT MEMORY-LIKE T-CELLS AND THEIR USE
MX2019002223A (es) Procedimiento mejorado para el cultivo de algas.
MX2020003314A (es) Expansion y uso de fracciones de celulas nk ampliadas.
JOP20220206A1 (ar) الخلايا التائية واستخداماتها
IL281231A (en) Methods of continuous cell culture
MX2019013614A (es) Seleccion y uso de fracciones de celulas del cordon umbilical adecuadas para trasplante.
ZA201907623B (en) T cells with reduced surface fucosylation and methods of making and using the same
PL415351A1 (pl) Sposób namnażania in vitro komórek T regulatorowych (Treg)
SG10201811177SA (en) Cell culture methods and media comprising n-acetylcysteine
WO2018211509A3 (en) SELECTION AND USE OF FRACTIONS OF OMBILICAL CORD CELLS SUITABLE FOR TRANSPLANTATION